Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Blood

• Publication date

  1993-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V81.2.538.538PMID 8422470
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network.

  1992cited by this paper
• Intravenous immunoglobulin in combination with other prophylactic and therapeutic measures

  1992cited by this paper
• IgM anti‐idiotypes that block anti‐HLA antibodies: naturally occurring or immune antibodies?

  1991cited by this paper
• Simple method for differentiating between HLA and platelet‐specific antibodies by flow cytometry

  1991cited by this paper
• The alloantibody response of pregnant women and its suppression by soluble HLA antigens and anti-idiotypic antibodies.

  1991cited by this paper
• The physiology of anti-idiotypic interactions: from clonal to paratopic selection.

  1991cited by this paper
• THE DEVELOPMENT AND SPECIFICITY OF ANTIIDIOTYPIC ANTIBODIES IN RENAL TRANSPLANT RECIPIENTS RECEIVING SINGLE‐DONOR BLOOD TRANSFUSIONS

  1989cited by this paper
• Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin

  1989cited by this paper
• Anti‐idiotypes against Autoantibodies in Normal Immunoglobulins: Evidence for Network Regulation of Human Autoimmune Responses

  1989cited by this paper
• Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig.

  1989cited by this paper
• Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin.

  1989cited by this paper
• INDUCTION OF ANTIIDIOTYPIC ANTIBODIES TO DONOR HLA‐A2 FOLLOWING BLOOD TRANSFUSIONS IN A HIGHLY SENSITIZED HLA‐A2+ RECIPIENT

  1988cited by this paper
• Transient platelet and HLA antibody formation in multitransfused patients with malignancy

  1988cited by this paper
• Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins.

  1988cited by this paper
• Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients.

  1987cited by this paper
• Determination of antiidiotypic antibodies to anti-HLA IgG following blood transfusions.

  1987cited by this paper
• Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP.

  1984cited by this paper
• Anti-idiotypic antibodies to anti-HLA receptors induced by pregnancy.

  1983cited by this paper
• Regulatory idiotopes and immune networks: a hypothesis.

  1982cited by this paper
• Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized

  1981cited by this paper
• Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension.

  1981cited by this paper
• Suppression of transfusion-related alloimmunization in intensively treated cancer patients.

  1981cited by this paper
• Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized.

  1981cited by this paper
• The Natural History of Alloimmunization to Platelets

  1978cited by this paper
• Antibody response in patients with acute nonlymphocytic leukemia

  1976cited by this paper

• Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients

  2024cites this paper
• Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.

  2023cites this paper
• Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects

  2023cites this paper
• Alloantibodies and Platelets

  2020cites this paper
• Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.

  2020cites this paper
• Refractoriness to platelet transfusion in the presence of anti-HLA antibodies—reassessing the alloantibody hypothesis

  2019cites this paper
• HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management.

  2012cites this paper
• In HPA 1a-immunized women the decrease in anti-HPA 1a antibody level during pregnancy is not associated with anti-idiotypic antibodies

  2009cites this paper
• Slow responses to standard dose rituximab in immune thrombocytopenic purpura

  2009cites this paper
• Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches.

  2005cites this paper
• Platelet alloimmunization after long‐term red cell transfusion in transfusion‐dependent thalassemia patients

  2005cites this paper
• Immunology of Leucocytes, Platelets and Plasma Components

  2005cites this paper
• Understanding platelet function through signal transduction.

  2003cites this paper
• Gamma-globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response.

  2002cites this paper
• Selecting donors of platelets for refractory patientson the basis of HLA antibody specificity

  2000cites this paper
• The evaluation and management of platelet refractoriness and alloimmunization.

  2000cites this paper
• Prevention and Management of Platelet Transfusion Refractoriness

  1999cites this paper
• [Transfusion of platelet concentrates].

  1999cites this paper
• Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation—a prospective analysis

  1998cites this paper
• Immune Mechanisms of Platelet Refractoriness

  1998cites this paper
• Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action.

  1998cites this paper
• Diagnosis and treatment of patients refractory to platelet transfusions.

  1998cites this paper
• Platelet transfusion therapy.

  1996cites this paper
• Use of Intravenous Immunoglobulins in Haematological Disorders

  1996cites this paper
• Alloimmunization and platelet transfusion.

  1996cites this paper
• Autoantibodies in Therapeutic Preparations of Human IgG (IVIg)

  1996cites this paper
• Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation.

  1996cites this paper
• Mechanisms of action of intravenous immune globulin in immune‐mediated diseases

  1996cites this paper
• Long‐term follow‐up testing of red cell alloantibodies

  1994cites this paper
• Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases.

  1994cites this paper
• IMMUNOMODULATION OF AUTOIMMUNE AND SYSTEMIC INFLAMMATORY DISEASES WITH INTRAVENOUS IMMUNOGLOBULIN

  1994cites this paper
• V Region‐Mediated Selection of Autoreactive Repertoires by Intravenous Immunoglobulin (i.v.Ig)

  1994cites this paper
• Immune modulating effects of intravenous immunoglobulin (IVIg) in autoimmune diseases.

  1994cites this paper
• Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)

  1993cites this paper
• Anti-Idiotypic Regulation of the Alloimmune Response in Patients Transfused with Platelet Concentrates

  1993cites this paper